REGN Regeneron Pharmaceuticals

Q1 2025 10-Q

Filed: Apr 29, 2025Period ending Mar 31, 2025

Health Care

Pharmaceutical PreparationsSEC EDGAR

Regeneron Pharmaceuticals (REGN) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on Apr 29, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q1 2025 10-Q

Risk Factors

• New risk added: EYLEA HD FDA approval in August 2023 triggered dependence risk on EYLEA HD commercialization success
• Updated risk: EYLEA U.S. net sales declined 39% YoY due to increased competition and market pressures, impacting revenue materially

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$3.0B

Net Income

$809M

Net Margin

26.7%

Source: XBRL data from Regeneron Pharmaceuticals Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other Regeneron Pharmaceuticals Quarterly Reports

Q3 2025 10-Q

Q2 2025 10-Q

Get deeper insights on Regeneron Pharmaceuticals

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.